A tabulation of carcinogenic potency (TD50) by species for 492 chemicals that induce tumors in rats or mice is presented. With the use of the Carcinogenic Potency Database, experimental results are summarized by indicating in which sex-species groups the chemical was tested and the respective evaluations of carcinogenicity. A comparison of three summary measures of TD50 for chemicals with more than one positive experiment per species shows that the most potent TD50 value is similar to measures that average values or functions of values. This tabulation can be used to investigate associations between rodent potency and other factors such as mutagenicity, teratogenicity, chemical structure, and human exposure.
method must be selected to summarize the potency of a carcinogen when there is more than one potency estimate for it. Additional information to summarize the experimental results includes the number of sexspecies groups tested and the evaluations of carcinogenicity in each group.
In this paper we present a table summarizing carcinogenic potency in rats and mice for the 492 chemicals that have positive results in the CPDB; we also indicate in which sex-species groups the chemical was tested and the respective evaluations of carcinogenicity. Our intent is that this summary compilation will be a useful reference source for the scientific and regulatory communities, and that it will facilitate the use of our larger published plots of the CPDB. The larger plots provide detailed information on each experiment including the species, sex, strain, route of administration, duration of exposure and of experiment, dose levels, target sites, shape of the dose response, estimates of carcinogenic potency and the confidence limits surrounding it, statistical significance of the carcinogenic dose response, tumor incidences, and bibliographic citation to the published paper or to the NCI/NTP Technical Report.
Methods
Our analyses are based on the chemicals reported in the CPDB (4) (5) (6) , which has been fully described in Gold et al. (4) as to bioassay inclusion criteria, protocol characteristics and derived variables. The database is organized by chemical using a plot format and includes bioassay results from two sources: papers published in the general literature through 1984, and NCI/NTP Technical Reports published through May 1986. All experiments in the database meet a specific set of inclusion criteria that were designed to permit the estimation of carcinogenic potency; therefore, reasonable consistency of experimental protocols is assured. Rodent bioassays are included in the database only if the test agent was administered alone rather than in combination with other substances; if the bioassay included a control group; if the route of administration was either diet, water, gavage, inhalation, IV injection or IP injection; and if the length of experiment in rodents was at least 1 year with dosing for at least 6 months. For the CPDB, we do not evaluate the evidence for carcinogenicity in an experiment; rather, we report the evaluation of the published author and calculate the statistical significance of the tumorigenic dose response in the experiment.
Carcinogenicity
Our tabular compilation of results by sex-species group and of carcinogenic potency by species is restricted to chemicals identified as carcinogens in our database. We classify the results of an experiment as either positive or negative on the basis of the author's opinion in the published paper, and we include in the present publication only those chemicals that have been evaluated as positive by the author of at least one experiment. In some cases authors do not clearly state their evaluation, and in some NCI/NTP Technical Reports the evidence for carcinogenicity is considered only suggestive; in our analyses we consider these cases as lacking clear evidence of carcinogenicity and do not use them to identify a chemical as positive. We use the author's opinion to determine positivity because it often takes into account more information than statistical significance alone, such as historical control rates for particular sites, survival and latency, and/or dose response. Generally, this designation by author's opinion corresponds well with the results of statistical tests for the significance of the dose-response effect (4,7).
In our tabular compilation of positivity by sexspecies group for each of the 492 chemicals classified as positive, we indicate whether the compound was tested in each group and list the strongest level of evidence for carcinogenicity based upon any author's evaluation in either the general literature or the NCI/NTP. The strongest evaluation is clear evidence of carcinogenicity (+). When there was no such evaluation in one of the sex-species groups, but the compound was tested by NCI/NTP and their evaluation was stronger than "no evidence of carcinogenicity" (-), we indicate whether that NCI/NTP evaluation was "some evidence of carcinogenicity" (A), "equivocal" (E) or "inadequate bioassay" (I). These evaluations correspond to the opinions reported in our published plots; we note that in a few borderline cases our interpretation of the Technical Reports differs from those recently tabulated by Haseman et al. (8) .
Carcinogenic Potency Values
In our analyses of carcinogenic potency we use our numerical index, the TD50, which has been fully described in Sawyer et al. (9) and in Peto et al. (10) , and which is reported for each target site in our published plots. Briefly, TD50 may be defined as follows: For a given target site(s), TD50 is the chronic dose rate in milligrams per kilogram body weight per day that would induce tumors in half the test animals at the end of a standard lifespan for the species in the absence of tumors in control animals. Since the tumor(s) of interest often occurs in control animals, TD50 is more precisely defined as the chronic dose rate that will halve the probability of remaining tumor-free throughout the standard lifespan of the species (9, 10 (4) . For these cases we use the 99% upper confidence limit of TD50 as a replacement for the TD50.
Results
In Table 1 Table 1 ). There are 18 such substances in rats and 12 in mice. For these carcinogens, any summary measure of We also compared the extreme cases (TD50 values discrepant by > 10-fold) to all other chemicals in Table 1 with more than one positive experiment, in terms of how often they were tested. In mice, 92% of the extreme cases were tested more than twice compared to 33% of all other cases; in rats, 89% of extremes were tested more than twice compared to 42% of others. There are similar differences in the number of positive tests for the two groups. Thus, when there are extreme differences between TD50 values from different tests of the same chemical, the selection of the least and most potent ratio for the cases that were not extreme (i.e., differed by less than a factor of 10) was 1.09 for mice and 1.25 for rats. We found that three-quarters of the extreme cases with a ratio > 10 were above this median in each species. This result is not surprising since generally the TD50 value is restricted by the maximum dose tested in a bioassay, i.e., a statistically significant TD50 cannot be very far from the administered dose, given the usual experimental design (13) .
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